• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: MDXXF )

    0.2045 +0.0070 (+3.54%)
    Streaming Delayed Price Updated: 12:11 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about MDXXF

    PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial
    PharmAla Biotech will supply GMP LaNeo MDMA to Mt. Sinai Health System for clinical research, advancing therapy for neurological disorders. 
    Via Benzinga
    PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
    PharmAla Biotech will supply the University of Texas, San Antonio with a novel LaNeo MDMA dosage form for a clinical trial, advancing MDMA research and innovation. 
    Via Benzinga
    PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
    PharmAla Biotech to supply MDMA for a clinical trial at Harvard's Maclean Hospital. Company also explores European distribution at CPHI Milan Conference. 
    Via Benzinga
    PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract
    PharmAla Biotech partners with Johns Hopkins to supply MDMA for clinical trials, terminates contract with Red Light Holland, and presents new APA-01 research at the EBPS Workshop. 
    Via Benzinga
    PharmAla Launches MDMA Clinical Trial Tool for Researchers
    From PharmAla Biotech
    Via GlobeNewswire
    PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
    From PharmAla Biotech
    Via GlobeNewswire
    Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
    Red Light Holland and PharmAla achieve psilocybin extraction milestone, advancing API development for scalable medical products. Read now! 
    Via Benzinga
    Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
    Via Benzinga
    Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
    From PharmAla Biotech
    Via GlobeNewswire
    Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
    Via Benzinga
    Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
    Via Benzinga
    PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
    Via Benzinga
    Topics Intellectual Property
    Exposures Intellectual Property
    Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
    Novel Composition of MDMA Enantiomers leading to next-generation MDMA possibilities 
    From PharmAla Biotech
    Via GlobeNewswire
    Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
    Via Benzinga
    Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
    Novel MDMA-Like Drug Could Be Used for Numerous Neurological and Psychiatric Indications 
    From PharmAla Biotech
    Via GlobeNewswire
    Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
    PharmAla now first company to supply both MDMA and Psilocybin into the Australian Market 
    From PharmAla Biotech
    Via GlobeNewswire
    Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
    Via Benzinga
    Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.